Merck & Co.
Merck & Co., Inc. (NYSE: MRK) is a global health care company that develops and sells prescription medicines, biologic therapies, vaccines and animal health products. Its Pharmaceutical segment supplies human medicines and pediatric, adolescent and adult vaccines to wholesalers, retailers, hospitals, government… From the company’s description.
In fiscal 2025, Merck & Co. reported revenue of $65.01B, up 1.3% from fiscal 2024, and net income of $18.26B. Its operating margin was 32.6%, and operations generated $16.47B in cash. Over the twelve months to Jun 30, 2026, revenue was $66.57B.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Merck & Co. does
In the company’s own words
Merck & Co., Inc. (NYSE: MRK) is a global health care company that develops and sells prescription medicines, biologic therapies, vaccines and animal health products. Its Pharmaceutical segment supplies human medicines and pediatric, adolescent and adult vaccines to wholesalers, retailers, hospitals, government agencies, physicians and managed health care providers. Its Animal Health segment sells veterinary pharmaceuticals and vaccines, health management services, and digitally connected animal identification, traceability and monitoring products to veterinarians, distributors, farmers, animal producers and pet owners. Key brands include Keytruda, Gardasil, Januvia, Bridion, Bravecto and Nobivac. In fiscal 2025, the Pharmaceutical segment generated $58.1 billion in sales and Animal Health generated $6.4 billion; total company sales were $65.0 billion. Its website is www.merck.com.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- RAHWAY, NJ
- Fiscal year end
- December
- CIK
- 310158
- SIC
- 2834
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Merck & Co. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Superinvestors in Merck & Co. · what they did last quarter
Share of each manager’s reported 13F portfolio. Change is in shares held, since the previous quarter.
Largest fund holders · Merck & Co.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Merck & Co.’s bonds, as funds hold them
Funds report holding 50 issues of Merck & Co.’s debt, $5.69B at market value — what funds hold, not the company’s total debt. Weighted-average coupon 4.29%, maturing 2027 to 2065.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Fund ownership is a subset of institutional 13F ownership — the two describe overlapping populations and must not be added together.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Merck & Co. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Merck & Co.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Merck & Co.'s last four quarterly filings that the numbers alone won't show?”